DailyIQ
Last updatedjust now

DGX·Quest Diagnostics Incorporated

$233.58
+3.12 (+1.35%)
Overnight$233.43-0.15 (-0.06%)
High
$234.97
Open
$231.32
Market Cap
25.61B
52W High
$248.84
Low
$231.32
P. Close
$233.58
P/E
24.12
52W Low
$171.17
Fwd P/E
19.36
DailyIQ Est.
$252.52
Inst. Ownership
42.0%
Short Interest
3.08%
Days to Cover
2.7
Div. Yield
1.45%
Next Ex-Div
~Jan 4
Div. Growth
14+ yrs
Technical Score (1D)
75
BULLISH
News Sentiment
57
BULLISH
The 1D chart for Quest Diagnostics Incorporated (DGX) is putting up a BUY signal at a score of 75 - a reading that places it in the top tier of technical strength. Momentum is strong and the trend bias is firmly bullish. Sentiment at 57 is aligned with the move, meaning the news backdrop and the price trend are reinforcing each other rather than diverging. Price action is constructive. Continuation setups at this level of conviction typically favor buying dips toward $221.73 over chasing the current price. Traders with existing positions are managing risk around that level, with $240.21 as the measured upside reference. Trends this clean don't need much active management - the main risk is over-trading around a setup that's already working. Trailing risk toward $221.73 and letting $240.21 act as the next checkpoint, rather than taking profits prematurely on strength, is typically the higher-expectancy approach when strong trend structure and aligned with sentiment are both confirming the same direction.
LOW TARGET
$204 -12.6%
2 analysts
MEAN TARGET
$249 +6.6%
14 analysts
HIGH TARGET
$265 +13.5%
9 analysts
PRICE RANGE
$204.00 - $265.00
SB / B / H / S / SS
6/7/10/1/1
DAILYIQ EST.
$252.52 (+8.2%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Symbol
DGX
Description
Quest Diagnostics is a leading provider of diagnostic testing and related services, operating primarily within the United States and internationally. The company's core business centers on delivering crucial diagnostic information, encompassing a broad range of clinical testing, including routine, specialized, and anatomic pathology services. Quest Diagnostics' value proposition lies in providing this essential information to a diverse client base, including physicians, hospitals, health plans, and pharmaceutical companies, among others. Leveraging a comprehensive network of laboratories, patient service centers, and healthcare professionals, Quest Diagnostics delivers its services under the Quest Diagnostics brand and several other established brands. Furthermore, the company offers risk assessment services and IT solutions for healthcare organizations, solidifying its position as a key player in the diagnostic healthcare landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
52,424 shares
$11.9M
WENTWORTH TIMOTHY C-
Award/Grant135 shares2026-10-01
Davis J. E.CEO and President
Sell10,000 shares2026-09-01
PREVOZNIK MICHAEL ESVP & General Counsel
Option Exercise22,677 shares2026-08-28
PREVOZNIK MICHAEL ESVP & General Counsel
Gift1,000 shares2026-08-28
PREVOZNIK MICHAEL ESVP & General Counsel
Sell430 shares2026-08-28
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
33.2%
Net Margin
9.0%
Revenue CAGR
2.8%
Current Ratio
1.04x
Debt / Equity
0.79x
Return on Equity
13.8%
Earnings Summary
Quest Diagnostics (DGX) is a leading provider of diagnostic testing and related services, operating primarily in the United States and internationally. The company delivers a broad spectrum of clinical testing, including routine, specialized, and anatomic pathology services, and also offers risk assessment and IT solutions to healthcare organizations, positioning it as a key player in the diagnostics & research sector. In the most recent quarters, Quest posted steady revenue growth, with Q4 2025 revenue at $2.806 billion versus $2.761 billion in Q3 2025, and Q1 2026 revenue at $2.895 billion, a 2.5% increase from the prior quarter. EPS also rose, with Q4 2025 EPS at $2.42 slightly below the $2.455 estimate, while Q1 2026 EPS of $2.50 exceeded the $2.367 estimate, reflecting a pattern of beating earnings expectations in three of the last four quarters. Historically, the company has maintained a consistent upward trajectory in both revenue and EPS, with YoY revenue growth hovering around 4–5% over the past three years and EPS growth exceeding analyst forecasts in most periods, indicating disciplined cost management and a robust client base. Recent news highlights include a modest price target adjustment by Evercore ISI, signaling a cautious view amid competitive pressures, and a technical breakout signal from ChartMill suggesting potential upside if the stock confirms a breakout. Additionally, a study in The Journal of Molecular Diagnostics reported high specificity and sensitivity for the Haystack MRD liquid biopsy test, reinforcing Quest’s oncology diagnostics capabilities.

EPS

EstBeatMiss
$2.25$2.50$2.74$2.99$3.23Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.87 - -
Q2'26$2.82$3.12+10.5%
Q1'26$2.37$2.50+5.6%
Q4'25$2.45$2.42-1.4%
Q3'25$2.50$2.60+3.9%
Q2'25$2.57$2.62+1.9%

Revenue

EstBeatMiss
$2.7B$2.8B$2.9B$3.0B$3.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.1B - -
Q2'26$3.0B$3.0B+1.3%
Q1'26$2.8B$2.9B+2.4%
Q4'25$2.8B$2.8B+0.9%
Q3'25 - $2.8B -
Q2'25 - $2.8B -

Market Data

DGX Stock Snapshot

BULLISH75/100
$233.43−$0.15 (0.1%)
Market cap
25.61B
P/E ratio
24.1
Day range
$231.32 – $234.97
News sentiment
57/100 · Neutral
Analyst target
$248.80 (+6.6%)
Consensus
Hold · 25 analysts
52-week range+36.4% off low · -6.2% from high
$171.17$248.84
Price $233.43 DailyIQ Est. $252.52

DGX's technical picture is constructive, with trend and momentum pointing the same direction. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into DGX?

FAIR

At today's price, Quest Diagnostics Incorporated needs to grow free cash flow about 2.4% a year for the next 10 years to justify its valuation at a 7.03% cost of capital. Over its actual history it has compounded free cash flow at 3.3% a year, so the market is asking for 0.9 percentage points below its own delivered rate. On that basis DGX looks priced roughly in line with its own growth record.

Implied FCF growth
2.4%
Historical FCF CAGR
3.3%
Growth gap
-0.9 pts
Verdict
FAIR
Discount rate (WACC)
7.03%
Beta
0.44

Behaviour On Record

What DGX's own history says about today's numbers

Realized volatility (21d)
31.0% 90th pct
Below its peak
-5.7%
vs 200-day average
+12.3%
Up days (1y)
49%

Quest Diagnostics Incorporated is currently running 31.0% annualised volatility over the last 21 sessions. Measured against DGX's own 13 years of daily returns rather than a market-wide average, that is the 90th percentile — elevated for this stock, against a typical reading of 19.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

DGX is trading -5.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.9%, and the deepest was -39.3% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +12.3% from its 200-day moving average. Against every other day in its history, that gap ranks at the 83rd percentile — a wider gap than this stock usually carries. Over the past year DGX closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, DGX finished the month higher 10 of 14 times, with a median return of +1.7% and an average of +2.1%. Its strongest month historically has been April at +4.1% on average, its weakest September at -1.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: DGX has opened more than 2% away from the prior close in 72 of 3,268 sessions (2.2% of the time), with the largest gaps running +6.4% and -9.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, DGX moved an average of 1.5% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.2% and a largest of -2.5%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against DGX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of DGX's sector?

Quest Diagnostics Incorporated sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for DGX?

CallsPuts

For Quest Diagnostics Incorporated's nearest expiry (2026-10-16, 1 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 3.61), with at-the-money implied volatility around 60.8%. The options market is pricing roughly a ±3.1% move by that expiry — a range of about $217.48–$231.22.

Put/call ratio (2026-10-16)
3.61
ATM implied volatility
60.8%
Total open interest
4,853
Expected move by 2026-10-16
±3.1% ($217.48–$231.22)

Analyst Rating Changes

Are analysts turning bullish or bearish on DGX?

Barclays most recently reiterated its rating on Quest Diagnostics Incorporated to Overweight on Oct 7, 2026 with a price target of $260 (from $250). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Barclays — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysMaintainedOverweight$250 → $260
Sep 21, 2026Truist SecuritiesMaintainedHold$250 → $260
Sep 8, 2026UBSMaintainedNeutral$232 → $245
Jul 28, 2026JP MorganMaintainedNeutral$220 → $250
Jul 25, 2026UBSMaintainedNeutral$220 → $232
Jul 24, 2026MizuhoMaintainedOutperform$235 → $260
Jul 24, 2026Truist SecuritiesMaintainedHold$225 → $250
Jul 24, 2026BarclaysMaintainedOverweight$230 → $250
Jul 24, 2026BairdMaintainedNeutral$236 → $255
Jul 13, 2026BairdMaintainedNeutral$232 → $236
Apr 22, 2026UBSMaintainedNeutral$210 → $220
Apr 22, 2026BairdMaintainedNeutral$224 → $229

Peers & ETF holders

DGX peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

57/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Quest Diagnostics (DGX) passed ChartMill’s Best Dividend screen, achieving a 2.1% yield and demonstrating robust profitability and a safe payout ratio. The company has maintained dividend growth for over a decade, reinforcing its status as a reliable income play. The rating signals steady cash flow and disciplined dividend policy, but does not indicate a significant shift in earnings guidance or strategic direction.
What did this article say?
Barclays analyst Luke Sergott upgraded Quest Diagnostics (NYSE:DGX) to an Overweight rating on October 7, raising the price target from $250 to $260. The upgrade reflects confidence in the company's earnings outlook and its competitive positioning in the laboratory services market. The new target suggests a modest upside for investors, though it is not considered a transformative catalyst. The move is part of Barclays’ broader coverage of the healthcare diagnostics sector.
What did this article say?
Barclays increased its price target for Quest Diagnostics (DGX) from $250 to $260, reflecting a more optimistic view of the company’s prospects. The brokerage maintained an overweight rating, indicating confidence that DGX will outperform the broader market. The adjustment signals that analysts expect stronger earnings growth and continued demand for diagnostic services.
What did this article say?
Evercore ISI reduced its price target for Quest Diagnostics (DGX) from $240 to $235 while keeping an in‑line rating. The adjustment reflects a modest view that the company’s valuation should be slightly lower than previously estimated. The change does not alter the overall overweight consensus among analysts. The move signals a cautious stance on Quest’s growth prospects amid competitive pressures.
What did this article say?
Quest Diagnostics (DGX) is slated to report Q3 earnings on October 22, 2026, with analysts forecasting diluted EPS of $2.85, a 9.6% increase from the prior year‑quarter. The company has consistently exceeded Wall Street estimates for the past four quarters, underscoring robust earnings performance. Fiscal 2026 EPS is projected at $11.15, up 13.2% from $9.85 in 2025, with further growth expected into 2027. These figures suggest a solid earnings trajectory and a positive outlook for DGX investors.
What did this article say?
On October 2, ChartMill’s technical analysis indicated that Quest Diagnostics (DGX) had a breakout setup with a trend rating of 7 and a setup rating of 8. The analysis identified a breakout entry point above $237.95 and support near $230.87. The report suggested that the stock could move higher if the breakout is confirmed, but it did not provide a definitive forecast or guarantee a sustained rally. The signal reflects a mild tailwind for DGX, with no immediate material impact on the company’s fundamentals or earnings outlook.
What did this article say?
A study published in The Journal of Molecular Diagnostics on Oct. 1, 2026 demonstrated that the Haystack MRD liquid‑biopsy test achieved 100% specificity and high sensitivity for detecting residual or recurrent disease in specimens from the DYNAMIC colorectal cancer trials. The analysis, conducted by Quest Diagnostics (NYSE: DGX), validated the test’s performance across 23 solid‑tumor types. The findings support the clinical utility of Haystack MRD for guiding post‑treatment decisions and may enhance DGX’s competitive positioning in the ctDNA market.
What did this article say?
Quest Diagnostics’ stock climbed 36.3% year‑to‑date, outperforming the broader market and its industry peers. The rally was driven by robust demand in advanced diagnostics, especially oncology, and the company’s expansion across physician, hospital and consumer testing channels. Adoption of AI and automation has improved operational efficiency and reduced costs, reinforcing the firm’s growth trajectory. The performance underscores a positive outlook for DGX’s market positioning and earnings prospects.
What did this article say?
Quest Diagnostics (DGX) has announced a partnership with Apple Health that lets iPhone and iPad users order a preventive lab panel of over 50 biomarkers for $119. The move is expected to broaden consumer access to testing and reinforce DGX’s position as a digital health lab engine. While the stock has already rallied 35% YTD, analysts note that the valuation may still be 5% below fair value, suggesting a modest upside. The integration could drive incremental revenue and strengthen DGX’s competitive moat against other lab and health‑testing players.

Technical Analysis

Real-time indicators across multiple timeframes

75
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $9.30B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy14,392,08212.95%$2.50B2026-01-29
BlackRock, Inc.▲ Buy9,275,4118.35%$1.97B2026-08-07
JPMorgan Chase & Co▼ Sell3,520,4383.17%$748.59M2026-08-12
Geode Capital Management, LLC▲ Buy3,137,8732.82%$662.58M2026-08-12
Morgan Stanley▼ Sell2,460,4972.21%$521.50M2026-08-13
Bank of America Corp▲ Buy1,935,1331.74%$410.15M2026-08-14
Wells Fargo & Company▼ Sell1,751,2201.58%$371.17M2026-08-14
Davis Selected Advisers▼ Sell1,555,6121.40%$329.78M2026-08-11
Norges Bank▲ Buy1,406,6201.27%$298.13M2026-08-12
FMR LLC (Fidelity)▲ Buy1,398,7351.26%$296.46M2026-08-13
Invesco Ltd.▼ Sell1,379,1151.24%$292.30M2026-08-14
Northern Trust Corp▲ Buy1,127,4541.01%$238.96M2026-08-13
Goldman Sachs Group Inc▼ Sell982,6940.88%$208.28M2026-08-14
AllianceBernstein L.P.▼ Sell625,8940.56%$122.66M2026-08-14
Citigroup Inc▲ Buy315,5840.28%$66.89M2026-08-03
Balyasny Asset Management L.P.▲ Buy275,3710.25%$58.36M2026-08-14
Marshall Wace, LLP▲ Buy269,7600.24%$57.18M2026-08-13
Citadel Advisors LLC▼ Sell133,2110.12%$28.23M2026-09-02
Squarepoint Ops LLC▼ Sell117,8310.11%$24.97M2026-08-14
Gotham Asset Management, LLC▼ Sell117,5330.11%$24.91M2026-08-14
Adage Capital Partners GP, L.L.C.▲ Buy106,3030.10%$22.53M2026-08-14
Wellington Management Group LLP▼ Sell87,5700.08%$18.56M2026-08-14
AQR Capital Management LLC▲ Buy61,1960.06%$12.92M2026-08-14
Prudential Financial Inc▲ Buy60,1340.05%$12.75M2026-08-12
Neuberger Berman Group LLC▲ Buy53,2240.05%$11.28M2026-08-13
Q2 2026 flow:1.32M sh bought ($280.33M)1.56M sh sold ($329.56M)net -235.1K sh (−$49.23M)
Congressional Trading Activity
10 disclosed trades · ~$129.0K est. traded value · 5 buys, 5 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-302026-07-21
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-032025-12-11
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-10-302026-08-05
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-10-302026-08-05
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-07-242026-01-13
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-04-282026-01-13
Carol Devine MillerHouseWV01▼ Sell$15K - $50K2025-03-102026-08-13
Tommy TubervilleSenateAL▼ Sell$15K - $50K2024-01-032024-02-14
Tommy TubervilleSenateAL▲ Buy$1K - $15K2021-03-292021-07-23